Seattle Genetics down on light 2019 Adcetris sales guidance

Seattle Genetics Inc. (NASDAQ:SGEN) fell $8.73 (12%) to $65.02 Friday after announcing late Thursday 2019 guidance for Adcetris brentuximab vedotin sales below the consensus estimate. The move represents a market cap loss of almost $1.4 billion.

Seattle Genetics expects 2019 Adcetris sales

Read the full 418 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE